Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00433745|
Recruitment Status : Completed
First Posted : February 12, 2007
Results First Posted : July 8, 2014
Last Update Posted : July 8, 2014
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Drug: WT1 Peptide Vaccine
Although there was one partial response at 7 weeks, this patient went on to relapse as well.
Consequently, all 4 patients had rapid relapses despite vaccination. Accrual was stopped at 4.